§@ªÌ nightcatman (©]¿ß) ¬ÝªO Gossiping
¼ÐÃD ¤T»EÙæÓi¨Æ¥ó§Þ³N¦Wµü¾ã²z
®É¶¡ Thu Sep 25 10:50:26 2008
¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w¢w
ªá¤F´XÓ¤p®É²×©óª¦§¹¤F¤j³¡¥÷ªº¤T»EÙæÓi°Q½×¦ê
¤]¬Ý¤FFDA©M¼Ú·ùªºì¤å
µo²{ª©¤Wªº°Q½×¥æÂø¦UºØ¿ù»~©M¥¿½TªºÆ[©À
©Ò¥H¤~·Q¨ìnµo½g³o¤å
²@µLºÃ°Ýªº, ³o¦¸½Ã¥Í¸pªº³B¸m½T¦³¤£·í
¦ý§Ú·Q«ü¥X¥L̯u¥¿¿ù»~ªº¦a¤è¬O«Ü«nªº
§_«h¦UºØ¦ü¬O¦Ó«Dªºª§½×ÁÙ·|Ä~Äò¤U¥h
º¥ý§Ú·|¥ýÂç²M¤@¨Ç¦Wµü¤Î©M·§©À
µM«á¸ÑÄÀ¤@¤UFDA©M¼Ú·ùªºì¤å¬O¦bÁ¿¤°»ò
³Ì«á¤~¬OÓ¤H¹ï³o¾ã¥ó¨Æªº¬Ýªk
±µ¤U¨Ó¬O¥¿¤å
(1) ppm: §Ú·Q³oÓ¤j®a¤ñ¸û²M·¡, ppm´N¬Oparts per millionªºÁY¼g
¤]´N¬O¦Ê¸U¤À¤§¤@, ¦ý³o¨Ã¤£©óÅé¿n¤W©Î«¶q¤W, ¦]¦¹«e±
¦³¤H»¡¥¤¯»¬O©TÅé¨S¿ìªk´úppm, ¨Æ¹ê¤W¨Ã«D¦p¦¹, ½Ã¥Í¸p³W½d
¤¤©ÒºÙªºppm³æ¯Â¬O«ü¥¤¯»(©TÅé)Á`«¶q©M©Ò§tªº¤T»EÙæÓi«¶q
ªº¤ñ¨Ò¦Ó¤w, ¥Î©w¶qªº¥¤¯»ªw¤ô«á¦A¥h´ú¤T»EÙæÓi§t¶q, ¤@¼Ë
¥i¥H±o¨ì©M½Ã¥Í¸p³W½d©w¸q¤@Pªºppm
(2) ¤T»EÙæÓiªº¶q´ú:
¤@¯ë¬O¥ÎGC©ÎHPLC¨Ó´ú, «e±¦³ª§½×¨ì©³²{¦æ¶q´úªººë½T«×¨ìþ,
¦bFDA¤å¥ó¤¤, ³Ì§C°»´ú·¥(lower limit of detection, LOD)
¥i¥H§C¨ì10ppb, ¦ý¨º¬O³Ì¨Î¼ÆÈ, ¤@¯ë±¡ªp¤ULOD¬ù¦b50~100ppb
, ¦¹¼ÆÈ³QFDA©M¼Ú·ù³£±Ä¥Î, ¦b¦¹¤§¤Uªº¶q´úÈ´Nºâ¬O¦³, ¤]·|
³Qµø¬°¬O¹s, ¦]¦¹«e±¦³¤H»¡½Ã¥Í¸p©Òqªº2.5ppm¬O¶q´ú·¥ªº
»¡ªk, ¨Ã¤£¦¨¥ß, ¯u¥¿ªº¶q´ú·¥»·§C©ó¦¹
ªþ±a¤@´£, Áp¦X³ø¦³·s»D»¡¬Y¾ÇªÌÁnºÙFDA¹ï¤T»EÙæÓiªº¼Ð·Ç¬O
50ppb, ¸Ó¾ÇªÌ¤Þ¥Îªº´N¬O³oӼƦr, ¤£¹L¥L³o¬O¶Ã®M¼Æ¾Ú, LOD
©M¨î¼Ð·Ç®Ú¥»¬O¨â¦^¨Æ
(3) Tolerable Daily Intake (TDI):
³oÀ³¸Ó¬O³Ì³Q»~¸Ñªº¼ÆÈ¤F, º¥ý§ÚÌ¥²¶·¥ý¤F¸Ñ, TDI¬O¥Î¦b
"¤£¸Ó¦s¦b©ó¹«~¤¤" ªºª«½èªº, Acceptable Daily Intake
(ADI) ¤~¬O¥Î¦b¹«~²K¥[ª«¤Wªº, ¦]¦¹¬Ý¨ìTDI, ´Nªí¥Ü¤F¸Óª«½è
µ´¹ï¤£¸Ó³Qµø¬°¬O¹«~²K¥[ª«, ¦ÓÀ³¸Ó³Qµø¬°¬O¦³®`ª«½è
¥Ñ©ó¬OTDI¬O¹ï¦³®`ª«½è¦Ó¤£¬O¹ª«, ©Ò¥H°ò©ó¹D¼w¦]¯À, ¤HÅé
¹êÅç¬O¤£¥i¯àªº, ¥u¯à°µ°Êª«¹êÅç, ¦]¦¹«e±¦³¤H½èºÃFDA¤å¥ó
ùتºTDI¨S¦³°µ¤HÅé¸ÕÅç, ³o¬O§¹¥þnonsenseªº½èºÃ
¦ÓTDI¬O¥ÑNOAEL (no-observed-adverse-effect-levels)±o¨Ó,
¦p¦r±©Òz, NOAEL§Y¬O¦b¹êÅ礤¨S¦³Æ[¹î¨ì¥ô¦ót±²{¶Hªº¾¯¶q
¤W, ³o©MLD50¤£¦P, ¤£¬O¦º¤F¤~ºâ¦Ó¬O¥un¦³¥ô¦ó²§±`³£ºâ,
©Ò¥H«e±¦³¤H½èºÃTDI¥u¯à¤ÏÀ³P¦º²v¦Ó¤£¯à¤ÏÀ³P¯f²v, ³o¤@¼Ë
¬Ononsenseªº½èºÃ
¦bFDAªº¤å¥ó¤¤, ¤T»EÙæÓiªºNOAEL¬O 63 mg/kg bw/day, ³oÓ¼Æ
È¥²¶·¦A°£¥H10¥H®e³\ª«ºØ®t²§ªº·ÀI(¦]¬°°µªº¬O°Êª«¹êÅç),
µM«á¦A°£¥H10¥H®e³\ÓÅé®t²§ªº·ÀI, ³oºÙ¬° safety/uncertainty
factors (SF/UF), ³Ì«á©Ò±o¨ìªº 0.63 mg/kg bw/day ´N¬OTDI,
©Ò¥H«e±¦³¤H½èºÃ¦Ñ¹«¹êÅ礣¯à®M¥Î¨ì¤H¨¤W, ¦ý³o·ÀI¨ä¹ê¤w¸g
¦bTDIªºpºâ¹Lµ{ùر³Q¦ôp¶i¥h¤F
¯u¥¿¸Ó½èºÃªºÂI¬O¦~ÄÖ°ÝÃD, ¹ïÀ¦¥®¨à¦Ó¨¥, TDIÀ³¸Ó¦A¤U°,
¬Æ¦Ü¥i¤U°10¿³£¤£¬°¹L
(4) FDAªº¤å¥ó:
ì¤å¦b
http://www.cfsan.fda.gov/~dms/melamra.html
«Ü¦h¤H»~¸Ñ¤F³o¤å¥óªº¥Øªº, ³o¤å¥ó¨Ã¤£¬Onq¤@Ó¹«~¼Ð·Ç,
¦Ó¬O¥Ñ©ó·í¦~¦³«Ü¦h§t¤T»EÙæÓiªº¤¤°ê»sÃdª«¹«~¤Î¹}®Æ¶i¨ì¬ü°ê,
¦]¦¹¬ü°ê§Æ±æª¾¹D¥¦¦b½Þ¦×,Âû¦×,³½¦×,³JÃþ¤¤ªº´Ý¯d¶q¬O§_·|
¦³¦w¥þ¤WªºÅU¼{, º¥ý¥L̰µ¤F°Êª«¹êÅç¥h¦ôpTDI, µM«á¶q´ú¦b
¦UºØ¹ª«¤ºªº¤T»EÙæÓi´Ý¯d¶q, ±µµÛ³]p¤F¤TºØ±¡¹Ò¥h¦ôºâ¤HÅé
ªº¤T»EÙæÓiÄá¨ú¶q, ¨Ã¥B©MTDI¤ñ¸û, µ²ªGÅã¥Ü§Y¨Ï¦b³ÌÃaªº±¡ªp
¤U (Scenario 3, Worst case), ¤HÅéÄá¨ú¶q¤´Â»·§C©óTDI¨âÓ
¼Æ¶q¯Å¥H¤W
(5) ¼Ú·ùªº¤å¥ó:
ì¤å¦b
http://www.efsa.eu.int/cs/BlobServe...f?ssbinary=true
¼Ú·ùªºEFSA©MFDA°µ³o¤å¥óªº²z¥Ñ¤@¼Ë, ³£¬O¬°¤Fn¦]À³§t¤T»E
ÙæÓiªº¤¤°ê»sÃdª«¹«~¤Î¹}®Æªº¶i¤f, ¦ý¤£¦Pªº¬OEFSA¨Ã¨S¦³¥h
°µ¥ô¦óªº¹êÅç, ¦Ó¬O¥hreview¤F¤j¶qªº¬ã¨s¤åÄm¨Ó§@§PÂ_, ¦Ó
¥Ñ©óScientific Committee of Food (SCF)¦b¤§«e¹ï©ó²±¸Ë¹ª«
ªºª«½è¦³¤@Ó 0.5 mg/kg bw/dayªºTDI, ¦Ó¦¹¼ÆÈ¤S¤ñFDAªº§ó¤p
, ©Ò¥HEFSA«ØÄ³¼Ú·ù¦U°ê¥ç¤Þ¥Î¦¹¼ÆÈ°µ¬°¹ï¹ª«¤Î¹}®ÆªºTDI
(6) ª©¤Wªº°Q½×¤ÎÓ¤H¬Ýªk:
º¥ý¤£¯à¤£´£¨ìªº´N¬O¬Y¨Ç¤å¤¤¹ï©óppm©MTDIªºpºâ, ¦b¨º¨Ç¤å
¤¤¥H½Ã¥Í¸p©Òq¼Ð·Çªº2.5ppm¨Ópºâ¥¤¯»¤¤ªº¤T»EÙæÓi§t¶q, µM«á
»P¬ü°ê©Î¼Ú·ùªºTDI¤ñ¸û, ¨ÓÃÒ©ú½Ã¥Í¸p©Òqªº¼Ð·Ç¬O¦X²zªº
§Ún»¡ªº¬O, ¦b¼Æ¦r¤W, ¨º¨Ç¤å¤¤ªºpºâ¬O¥¿½Tªº, ·Ó³o¼Ëºâ¥X
¨ÓªºÄá¨ú¶q½T¹ê»·§C©óTDI, ¦ý¬O¦b·§©À¤W, ¥Î³o¼Ëªºpºâµ²ªG¥h
±À½×½Ã¥Í¸p©Òqªº¼Ð·Ç¬O¦X²zªº«oµLªk¦¨¥ß, ì¦]¦p¤U:
¥Ñ«ez, ¤T»EÙæÓiÀ³¬O¦³®`ª«½è¦Ó¤£¬O¹«~²K¥[ª«, ¦]¦¹¤~·|
¥ÎTDI¦Ó¤£¬OADI, ¦Ó¹ï©ó¨âªÌªººÞ²zÅÞ¿è¬O§¹¥þ¤£¦Pªº, ¹ï©ó
¹«~²K¥[ª«¦Ó¨¥, ¥i¥H®ø·¥ªº±NADIq¬°¦w¥þªº¤W, ¥un¤£¶W¹L
³oӼзǴN®e³\²K¥[, ¦ý¬O¹ï©ó¦³®`ª«½è¦Ó¨¥, TDIÀ³¸Ó¿n·¥ªº
°µ¬°Äµ§Ùªº¤U, ¤]´N¬O»¡¦Ü¤Önĵ§Ù¨ìTDIªºµ{«×, ¦ý¨Ã¤£©ó
ĵ§Ù¨ìTDIªºµ{«×´Nºâ¤F, ¨ä¼Ð·ÇÀ³¸Ón§C©óTDI¥B¶VÄY¶V¦n, ª½¨ì
¹Gªñ¨ìÀô¹Ò¤£¥iÁ×§Kªºµ{«× (¨Ò¦p®e¾¹ªº¬ªº|©Î°Êª«Å餺ªº´Ý¦s)
¦ý«ÜÅãµMªº, ½Ã¥Í¸pªº2.5ppm¨Ã¤£¬O¨Ì³o¼ËªºÅÞ¿è¨Ó³]©wªº,
¥¦¨Ã¨S¦³ºÉ¤O¥h¹Gªñ¨ìÀô¹Ò¤£¥iÁ×§Kªº³ÌÄY®æµ{«×, ¤]¦]¦¹µLªk
¯u¥¿±Æ°£¤H¬°²K¥[ªº¥i¯à©Ê, ¦Ó³o´N¬O½Ã¥Í¸p³Ì¤jªº¿ù»~©Ò¦b --
¥¦§â¤@Ó¦³®`ª«½è¥Î¹«~²K¥[ª«ªºÅÞ¿è¨ÓºÞ²z, ¦P®É³o¤]¬O«ez
pºâ¤åªºª¼ÂI©Ò¦b, ºâ¥X¨Óªº¼Æ¦r§C©óTDI, ¨Ã¤£¥Nªí³oӼзÇ
´N¬O¦X²zªº, ¦]¬°¨º¬OTDI¦Ó¤£¬OADI
¥H¤W´N¬O§ÚÓ¤H¹ï¦¹¨Æªº¬Ýªk
½Ð¤£§[«ü±Ð ÁÂÁÂ
---------
³o½g¤£¿ù